The Experts below are selected from a list of 1830 Experts worldwide ranked by ideXlab platform
Sneha V. Ghadiya - One of the best experts on this subject based on the ideXlab platform.
-
retrospective comparison of Voglibose or acarbose as an add on therapy to sulfonylureas in western indian patients with uncontrolled overweight obese type 2 diabetes
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
-
Retrospective comparison of Voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes
Diabetes & metabolic syndrome, 2015Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
Praful A. Talaviya - One of the best experts on this subject based on the ideXlab platform.
-
retrospective comparison of Voglibose or acarbose as an add on therapy to sulfonylureas in western indian patients with uncontrolled overweight obese type 2 diabetes
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
-
Retrospective comparison of Voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes
Diabetes & metabolic syndrome, 2015Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
Yoshiyuki Hamamoto - One of the best experts on this subject based on the ideXlab platform.
-
glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide Voglibose versus glimepiride a randomized cross over trial
Journal of Diabetes, 2018Co-Authors: Kanta Fujimoto, Sachiko Honjo, Yui Shibayama, Eriko Yamaguchi, Akihiro Hamasaki, Yoshiyuki HamamotoAbstract:BACKGROUND Glucose excursions and hypoglycemia are associated with cardiovascular complications. However, no studies have evaluated glucose excursions and the frequency of hypoglycemia in patients treated with mitiglinide/Voglibose versus glimepiride as add-on to dipeptidyl peptidase-4 inhibitor therapy. METHODS This cross-over trial included 20 patients with type 2 diabetes. After initiating vildagliptin 100 mg, patients were randomly assigned to receive mitiglinide 10 mg/Voglibose 0.2 mg three times daily for 3 days followed by glimepiride 1 mg once daily for the subsequent 3 days as add-on therapy, or vice versa. Glucose excursions and hypoglycemia frequency were measured using 24-h continuous glucose monitoring. Metabolic profile changes were evaluated using a meal tolerance test. RESULTS The mean glucose levels in the mitiglinide/Voglibose and glimepiride phases were identical (8.01 vs 8.24 mmol/L, respectively). However, during the mitiglinide/Voglibose phase compared with the glimepiride phase, the standard deviation of glucose (1.30 vs 2.10 mmol/L; P 10 mmol/L (0.18 vs 0.52 mmol/L per h; P < 0.001) were significantly lower. Hypoglycemia (glucose <3.8 mmol/L) was not observed during the mitiglinide/Voglibose phase, but occurred 0.35 times/day in those taking glimepiride. Moreover, the mitiglinide/Voglibose phase had higher premeal and lower post-meal glucose levels than the glimepiride phase. CONCLUSIONS Adding mitiglinide/Voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride.
-
Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/Voglibose versus glimepiride: A randomized cross‐over trial
Journal of diabetes, 2018Co-Authors: Kanta Fujimoto, Sachiko Honjo, Yui Shibayama, Eriko Yamaguchi, Akihiro Hamasaki, Yoshiyuki HamamotoAbstract:Glucose excursions and hypoglycemia are associated with cardiovascular complications. However, no studies have evaluated glucose excursions and the frequency of hypoglycemia in patients treated with mitiglinide/Voglibose versus glimepiride as add-on to dipeptidyl peptidase-4 inhibitor therapy. This cross-over trial included 20 patients with type 2 diabetes. After initiating vildagliptin 100 mg, patients were randomly assigned to receive mitiglinide 10 mg/Voglibose 0.2 mg three times daily for 3 days followed by glimepiride 1 mg once daily for the subsequent 3 days as add-on therapy, or vice versa. Glucose excursions and hypoglycemia frequency were measured using 24-h continuous glucose monitoring. Metabolic profile changes were evaluated using a meal tolerance test. The mean glucose levels in the mitiglinide/Voglibose and glimepiride phases were identical (8.01 vs 8.24 mmol/L, respectively). However, during the mitiglinide/Voglibose phase compared with the glimepiride phase, the standard deviation of glucose (1.30 vs 2.10 mmol/L; P < 0.001), mean amplitude of glycemic excursions (3.47 vs 5.28 mmol/L; P < 0.001), M-value (24.6 vs 70.0; P < 0.001), continuous overlapping net glycemic action for a 1-h time interval (22.6 vs 31.0; P < 0.001), and area under the curve >10 mmol/L (0.18 vs 0.52 mmol/L per h; P < 0.001) were significantly lower. Hypoglycemia (glucose <3.8 mmol/L) was not observed during the mitiglinide/Voglibose phase, but occurred 0.35 times/day in those taking glimepiride. Moreover, the mitiglinide/Voglibose phase had higher premeal and lower post-meal glucose levels than the glimepiride phase. Adding mitiglinide/Voglibose to vildagliptin therapy results in more efficient postprandial glucose control and less hypoglycemia than adding glimepiride. © 2018 The Authors. Journal of Diabetes published by John Wiley & Sons Australia, Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine.
-
Open Access Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes
2016Co-Authors: Sachiko Honjo, Hiroki Ikeda, Yukiko Kawasaki, Yoshiharu Wada, Yoshiyuki Hamamoto, Tomohisa Aoyama, Tetsuya Kimura, Kazuhiro Nomura, Hiroyuki KoshiyamaAbstract:Abstract: We investigated the efficacy and safety of miglitol, a new alpha-glucosidase inhibitor, by switching from Voglibose in Japanese patients with type 2 diabetes. Subjects included those who had previously been administered with Voglibose (n=90, 0.6mg/day). After Voglibose was changed into miglitol (150mg/day), HbA1C level, body weight and abdominal symptoms were evaluated six months later. HbA1C level was significantly decreased from 7.8±1.2 to 7.3±1.0% (P<0.01). Body weight showed a small but significant decrease after 6 months (62.5±11.0 to 62.1±12.3kg, P<0.01). There was no significant difference between frequencies of side effects before and after switching from Voglibose to miglitol. This study suggests the efficacy and safety of miglitol to improve glycemic control in Japanese patients with type 2 diabetes, who had previously been treated with Voglibose. Several recent studies have suggested that the clinical significance of postprandial hyperglycemia in relation to the risk of microvascular and macrovascular complications [1]. In 2007, International Diabetes Federation has announced the guideline which claimed that postprandial glucose should be less than 140mg/dl [2]. Miglitol is a new alpha-glucosidase inhibitor (-GI)
-
Efficacy and Safety of Miglitol: Switching Study from Voglibose in Japanese Patients with Type 2 Diabetes
The Open Diabetes Journal, 2009Co-Authors: Sachiko Honjo, Hiroki Ikeda, Yukiko Kawasaki, Yoshiharu Wada, Yoshiyuki Hamamoto, Tomohisa Aoyama, Tetsuya Kimura, Kazuhiro Nomura, Hiroyuki KoshiyamaAbstract:We investigated the efficacy and safety of miglitol, a new alpha-glucosidase inhibitor, by switching from Voglibose in Japanese patients with type 2 diabetes. Subjects included those who had previously been administered with Voglibose (n=90, 0.6mg/day). After Voglibose was changed into miglitol (150mg/day), HbA1C level, body weight and abdominal symptoms were evaluated six months later. HbA1C level was significantly decreased from 7.8±1.2 to 7.3±1.0% (P
Shaival K. Rao - One of the best experts on this subject based on the ideXlab platform.
-
retrospective comparison of Voglibose or acarbose as an add on therapy to sulfonylureas in western indian patients with uncontrolled overweight obese type 2 diabetes
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
-
Retrospective comparison of Voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes
Diabetes & metabolic syndrome, 2015Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
Hardik G. Dodiya - One of the best experts on this subject based on the ideXlab platform.
-
retrospective comparison of Voglibose or acarbose as an add on therapy to sulfonylureas in western indian patients with uncontrolled overweight obese type 2 diabetes
Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2016Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
-
Retrospective comparison of Voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes
Diabetes & metabolic syndrome, 2015Co-Authors: Praful A. Talaviya, Banshi Saboo, Hardik G. Dodiya, Shaival K. Rao, Shashank R Joshi, Vipul B. Modh, Sneha V. GhadiyaAbstract:Abstract Aim The study was aimed to investigate the effect of Voglibose or acarbose as an add-on treatment in overweight/obese type 2 diabetes (T2DM) patients who are uncontrolled with metformin and sulfonylureas (SUs) in Western part of India. Participants and methods A retrospective study included 77 participants (BMI ≥ 25 kg/m 2 ; HbA1c level > 8% and Results Voglibose showed significant reduction in HbA1c and bodyweight with short duration of treatment (6 months; P P P Conclusion Voglibose or acarbose as an add-on treatment with metformin and sulfonylureas in uncontrolled obese/overweight T2DM provides desired glycemic control, reduces bodyweight and improves lipid parameters with good tolerability profile.
